<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04854889</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-DAC202105</org_study_id>
    <nct_id>NCT04854889</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia</brief_title>
  <acronym>LODACA</acronym>
  <official_title>Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia (LODACA): a Phase 2, Single-arm, Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, single-center, single-arm, open-label trial. Simon's two-stage design is&#xD;
      performed to evaluate the efficacy of low-dose Decitabine in refractory aplastic anemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving a hematological response (any of the platelet response, erythroid response, and neutrophil response) after 4 cycles of low-dose decitabine</measure>
    <time_frame>At 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related adverse events</measure>
    <time_frame>Within 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a hematological response (any of the platelet response, erythroid response, and neutrophil response)</measure>
    <time_frame>Within 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with transfusion independence or decreased transfusion requirement</measure>
    <time_frame>Within 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute changes in blood cell count</measure>
    <time_frame>Within 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The utility score of EQ-5D-5L questionnaire</measure>
    <time_frame>Baseline, 20 weeks, 52 weeks</time_frame>
    <description>Health-related quality of life is measure by the EQ-5D-5L questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from the first decitabine to hematologic response</measure>
    <time_frame>Within 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hematologic response</measure>
    <time_frame>Within 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of relapse</measure>
    <time_frame>Within 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of clonal evolution</measure>
    <time_frame>Within 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Refractory Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive low-dose decitabine for 4 cycles and for another 6 cycles in extension study for patients achieving response during the first 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Demethylating agents</description>
    <arm_group_label>Decitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Subjects eligible for enrollment in the study should meet all of following criteria:&#xD;
&#xD;
          1. Diagnosis of acquired aplastic confirmed by peripheral blood and bone-marrow&#xD;
             examinations.&#xD;
&#xD;
          2. Refractory to standard first-line immunosuppressive therapy for at least 6 months,&#xD;
             including the combination of rabbit anti-thymocyte globulin (rATG) or porcine&#xD;
             anti-lymphocyte globulin (pALG) and cyclosporine (CsA); or ineligible for rATG/ pALG&#xD;
             and refractory to CsA alone.&#xD;
&#xD;
          3. Persistent decrease of blood cell count, including platelet &lt;30×10^9/L, and/or&#xD;
             hemoglobin &lt;90g/L, and/or absolute neutrophil count &lt;0.5×10^9/L.&#xD;
&#xD;
          4. Age ≥12 years old.&#xD;
&#xD;
          5. An Eastern Cooperative Oncology Group performance status score of 0 to 2 at screening.&#xD;
&#xD;
          6. Patients or their legally authorized representatives who have provided written&#xD;
             informed consent of their free will to participate in this study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Subjects must be excluded from participating in this study if they meet any of the&#xD;
        following criteria:&#xD;
&#xD;
          1. Diagnosis of inherited bone marrow failure disorders.&#xD;
&#xD;
          2. Bone marrow reticulin grade of ≥2.&#xD;
&#xD;
          3. Having a plan to take thrombopoietin (TPO) receptor agonists.&#xD;
&#xD;
          4. Having a plan to undergo hematopoietic stem cell transplantation within 1 year.&#xD;
&#xD;
          5. Subjects with hemolytic paroxysmal nocturnal hemoglobinuria clone.&#xD;
&#xD;
          6. Having abnormalities of cytogenetic abnormalities related to myelodysplastic syndrome&#xD;
             except for +8 or 20q- or -Y.&#xD;
&#xD;
          7. Previous or concurrent active malignancies with chemoradiotherapy, except localized&#xD;
             tumors diagnosed more than one year previously and treated surgically with curative&#xD;
             intent.&#xD;
&#xD;
          8. Cytopenias secondary to any other non-hematological disorders (e.g., liver cirrhosis,&#xD;
             active connective tissue disease, or chronic persistent infectious diseases).&#xD;
&#xD;
          9. Active infection not adequately responding to appropriate therapy.&#xD;
&#xD;
         10. Positive for anti-human immunodeficiency virus antibodies, or current infection of&#xD;
             hepatitis B virus or hepatitis C virus at screening.&#xD;
&#xD;
         11. Concurrent condition of acute hemorrhage in gastrointestinal tract or respiratory&#xD;
             tract, or central nervous system.&#xD;
&#xD;
         12. Dysfunction of liver: Alanine aminotransferase or aspartate aminotransferase or total&#xD;
             bilirubin is more than 2.0 times the upper limit of laboratory normal range.&#xD;
&#xD;
         13. Dysfunction of renal: creatinine clear rate is less than 30ml/min.&#xD;
&#xD;
         14. Clinically significant dysfunction of heart: class Ⅲ or Ⅳ of the New York Heart&#xD;
             Association classification.&#xD;
&#xD;
         15. Uncontrolled diabetes mellitus.&#xD;
&#xD;
         16. History of congestive heart failure, unstable angina pectoris, myocardial infarction,&#xD;
             arterial or venous thrombosis within one year before enrollment.&#xD;
&#xD;
         17. Lactating or pregnant women or patients who have no intention of using oral&#xD;
             contraceptives or birth control.&#xD;
&#xD;
         18. Subjects with psychiatric history or severe cerebrovascular disease with cognitive&#xD;
             disorder.&#xD;
&#xD;
         19. Participating in other clinical trials within 4 weeks before enrollment.&#xD;
&#xD;
         20. Hypersensitivity to decitabine or its components.&#xD;
&#xD;
         21. A history of decitabine, azacitidine, or other demethylation agents.&#xD;
&#xD;
         22. Receiving TPO-receptor agonists within 1 month before enrollment (other than patients&#xD;
             who are treated with TPO-receptor agonists and have no response after at least 4&#xD;
             months treatment).&#xD;
&#xD;
         23. Patients who are considered to be ineligible for the study by the investigator for&#xD;
             reasons other than above.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Shi, PhD</last_name>
    <phone>+8613752253515</phone>
    <email>shijun@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingyu Zhao, MPH</last_name>
    <phone>+8613752253515</phone>
    <email>zhaojingyu@ihcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regenerative Medicine Center</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Shi, PhD</last_name>
      <email>shijun@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Jun Shi</investigator_full_name>
    <investigator_title>Director of Regenerative Medicine Clinic Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

